4-antibody AG
This article was originally published in Start Up
Executive Summary
4-antibody AG aims to produce fully-human, "gold standard" antibodies using its unique combination of tested technologies. The trump card: it reckons it can skirt the IP blackout zone created by pioneers around well-validated targets, thereby opening up an alterrnative route into existing, billion-dollar antibody markets.
You may also be interested in...
MSM Protein Seizes Russian Antibody Opportunity
Benefiting from pharma's ongoing love affair with antibodies-illustrated most recently in Bristol-Myers Squibb's $2 billion purchase of Medarex--Boston-based start-up MSM Protein Technologies signed two drug discovery deals in late July.
MSM Protein Seizes Russian Antibody Opportunity
Benefiting from pharma's ongoing love affair with antibodies-illustrated most recently in Bristol-Myers Squibb's $2 billion purchase of Medarex--Boston-based start-up MSM Protein Technologies signed two drug discovery deals in late July.
Finding Human Monoclonals for Infectious Disease Vaccines
A recent publication shows the ability to make high-affinity, virus-specific human monoclonal antibodies in a matter of weeks from antibody-secreting plasma cells. The research suggests, at least theoretically, that an antibody vaccine could be developed for any infectious disease, using blood from either immunized or infected individuals.